To zinc or not to zinc for COVID-19 prophylaxis or treatment?

Kate Chander Chiang¹ and Ajay Gupta²,∗

Dear Editor,

We read with interest the recently published retrospective, observational study by Carlucci and colleagues examining zinc as a determinant of outcomes in hospitalized coronavirus disease 2019 (COVID-19) patients [1]. The authors found an association between improvement in certain outcomes when COVID-19 patients were treated with a combination of zinc, hydroxychloroquine and azithromycin, compared with treatment with hydroxychloroquine and azithromycin. However, as pointed out in a recent review of the study by Gbinigie and Akyea et al., the observed associations provide information about zinc in combination with other medications but not as a standalone treatment [2]. Notably, Carlucci and colleagues failed to find a benefit of zinc supplementation in severe COVID-19 patients requiring intensive care unit (ICU) care. Even though conclusive evidence is lacking, it is commonly believed that zinc may be beneficial in reducing the symptoms and duration of upper respiratory viral illnesses, including the common cold [3]. However, any beneficial effects of zinc supplementation in cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may be attributable to correction of subclinical zinc deficiency rather than the supraphysiological levels achieved in zinc-replete subjects [4]. Unfortunately, this cannot be determined from the Carlucci study since baseline zinc levels were not reported. Even though zinc has been shown to inhibit viral RNA-dependent RNA polymerase of SARS-CoV in vitro [5], there are no clinical studies of zinc for SARS-CoV 2003. While expected to be similar to SARS-CoV, the effect of zinc on SARS-CoV-2 RNA polymerase has not been reported to the best of our knowledge. In the interim, pending the results of ongoing randomized controlled clinical trials such as HELPCOVID-19 and ZnD3-CoVici, we suggest abundant caution when prescribing zinc for prophylaxis or treatment of COVID-19 for the reasons outlined below.

SARS-CoV-2 is generally transmitted by aerosol and possibly by the faecal–oral route [6]. Epithelial cells that comprise mucosal barriers in the respiratory tract or the gut produce interferons (IFNs), especially type III IFNs, as important components of the host innate antiviral response at mucosal barriers. Type III IFN, comprising IFN-λ 1, 2, 3 and 4, bind to interferon IFNL receptor 1 on epithelial cells in order to mount antiviral defence [7, 8]. Zinc can bind to interferon IFNL receptor 1, thereby blocking type III interferon (IFN) antiviral responses and interfering with the barrier function of respiratory and intestinal mucosa. In fact, in hepatitis C infection, higher zinc levels were associated with near doubling of viral load, putatively by inhibiting type III IFN action [8]. Amongst interferons, IFN-λ 2 and IFN-λ 3 serve as a potent defence against SARS-CoV-2 [7]. A deficient IFN-λ host response could facilitate viral replication in the upper respiratory tract, with spread of the virus down the airways and into the lungs, while promoting spread of the virus to contacts [7]. Thus, in early infection, at the upper respiratory mucosal barrier, it is unclear if supplemental zinc would help or hurt viral attack. Later in the course of infection, Broggi et al. reported that morbidity in COVID-19 patients correlates with high expression of type I and III IFNs in the lung, and that IFN-λ secreted by dendritic cells in the lungs causes damage to the lung epithelium, which increases susceptibility to bacterial superinfections [7]. Similarly, Major et al. found that IFN-λ hampers lung repair by inducing p53 and inhibiting epithelial proliferation and differentiation in a mouse model of influenza infection [9]. The results of these studies suggest that the location, timing and duration of IFN exposure and therefore zinc treatment are critical parameters underlying the success or failure of zinc in viral respiratory infections, including SARS-CoV-2.

Zinc, although essential for activity of many enzymes, transcription factors and signaling molecules, can be cytotoxic per se, inducing apoptosis in T cells, B cells and thymocytes [10, 11]. Incubation of peripheral blood mononuclear cells with zinc in vitro led to release of cytokines such as IL-1, IL-6, TNF-α and IFN-γ [12]. Zinc suppresses natural killer cell killing and T-cell functions while activating monocytes and in higher concentrations stimulating chemotaxis of neutrophil granulocytes [12]. Severe COVID-19 disease is characterized by a maladaptive immune response comprising dysregulation of myeloid cell...
It has recently been recognized that a maladaptive type 2 immune response normally triggered by helminths is associated with severity of COVID-19 disease [18]. Mast cells play a key role in type 2, T helper 2-mediated immune response in COVID-19 [19]. Mast cell activation is triggered by a perinuclear intracellular zinc wave mediated by various stimuli, including immunoglobulin E, that trigger inhibition of phosphatase activity and modulation of mitogen-activated protein kinase activation, thereby increasing expression of interleukin-6 (IL-6) and TNF-α [10]. IL-6 and TNF-α are biomarkers of severe COVID-19 [20], and upregulation of these biomarkers by zinc may explain the lack of benefit of zinc in severe COVID-19 cases observed by Carlucci et al.

Furthermore, zinc supplements, if consumed long-term for chemoprophylaxis, can interfere with absorption of dietary copper by competing with copper at the intestinal brush border during the luminal phase of absorption, thereby inducing copper deficiency [21]. Copper deficiency leads to anemia, leukopenia and immune suppression [21]. Copper is also a potent antioxidant [21], and copper deficiency could exacerbate oxidative stress in COVID-19. The population reference intake (PRI) for zinc is 7.2 to 12.7 mg/day for women and 9.4 to 16.3 mg/day for men [22]. However, relatively inexpensive supplements containing up to 50 mg elemental zinc per unit dose are readily available online or over the counter, thereby facilitating possible over supplementation in COVID-19 cases. Paracelsus, the 15th century physician who pioneered the use of chemicals and minerals in medicine, expressed the classic toxicology maxim ‘All things are poison, and nothing is without poison; the dosage alone makes it so a thing is not a poison’ [23]. Therefore, the presence or absence of zinc deficiency in the host, the dose of zinc and the duration of treatment are critical considerations when prescribing zinc in COVID-19 cases.

In conclusion, zinc administration in COVID-19 patients can influence the immune system positively by correcting any underlying zinc deficiency; and potentially negatively in zinc-replete patients by interfering with interferon lambda response, causing cytotoxicity to T and B cells and impairing TLR-4-mediated dendritic cell maturation. Randomized controlled trials are urgently needed to test the efficacy and safety of zinc in patients with COVID-19, and in the interim prudence is warranted when prescribing or consuming zinc supplements for prophylaxis or treatment of COVID-19.

Funding information
The authors received no specific grant from any funding agency.

Acknowledgements
We are grateful to Professor Peter A. McCullough, MD, MPH, Vice Chief of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA for a critical review of the manuscript.

Author contributions
A.G., conceptualized the framework for the manuscript; K.C.C. and A.G., wrote the original draft; and both authors reviewed and edited the final version.

Conflicts of interest
The authors declare that there are no conflicts of interest.

References
1. Carlucci PM, Ahuja T, Petrilli C, Rajagopalan H, Jones S, et al. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. J Med Microbiol 2020;69:1228–1234.
2. Gbinigie OA, Akyea RK. Should zinc be used for COVID-19 prophylaxis or treatment? A rapid review. Wellcome Open Res 2020;5:88.
3. Science M, Johnstone J, Roth DE, Guyatt G, Loeb M. Zinc for the treatment of the common cold: A systematic review and meta-analysis of randomized controlled trials. CMAJ 2012;184:E551-61.
4. Jackson JL, Lesho E, Peterson C. Zinc and the Common Cold: A Meta-Analysis Revisited. J Nutr 2000;130:1512S-55.
5. te Velthuis AJW, van den Worm SHE, Sims AC, Baric RS, Snijder EJ, et al. Zn(2+) inhibits coronavirus and arbovirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog 2010;6:e1001176.
6. Wu Y, Guo C, Tang L, Hong Z, Zhou J, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020;5:434–435.
7. Broggi A, Ghosh S, Sposito B, Spreafico R, Balzarini F, et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science 2020;369:706–712.
8. Read SA, O’Connor KS, Suppiah V, Ahlenstiel CLE, Obeid S, et al. Zinc is a potent and specific inhibitor of IFN-α3 signalling. Nat Commun 2017;8:15245.
9. Major J, Crotta S, Llorian M, McCabe TM, Gad HH, et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science 2020;369:712–717.
10. Yamasaki S, Sakata-Sogawa K, Hasegawa A, Suzuki T, Kabu K, et al. Zinc is a novel intracellular second messenger. J Cell Biol 2007;177:637–645.
11. Telford WG, Fraker PJ. Preferential induction of apoptosis in mouse CD4+CD8+αβTCR+CD3εo+CD45R0+ CD45RA+ T cells by zinc. J Cell Physiol 1995;164:259–270.
12. Ibs K-H, Rink L. Zinc-altered immune function. J Nutr 2003;133:1452S-6S.
13. Schulte-Schrepping J, Reusch N, Paclik D, Bafler K, Schlickeiser S, et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 2020;182:1419-1440.
14. Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, et al. Immunothrombotic Dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation 2020;142:1176–1189.
15. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19)
infections: A systemic review and meta-analysis. *Int J Infect Dis* 2020;96:131–135.

16. Kitamura H, Morikawa H, Kamon H, Iguchi M, Hojyo S, et al. Toll-like receptor-mediated regulation of zinc homeostasis influences dendritic cell function. 2006;7:971–977.

17. Sohn KM, Kim HJ, Cheon S, Jeong H, et al. Covid-19 patients upregulate toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis. *bioRxiv* 2020;2020.07.17.207878.

18. Lucas C, Wong P, Klein J, Castro TBR, Silva J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature* 2020;584:463–469.

19. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. *Int J Infect Dis* 2020;100:327–332.

20. Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med* 2020;26:1636–1643.

21. Fosmire GJ. Zinc toxicity. *Am J Clin Nutr* 1990;51:225–227.

22. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on dietary reference values for zinc. *EFSA Journal* 2014;12:3844.

23. Paracelsus. *Das Buch Paragranum. Septem Defensiones*: Christian Egenolff; 1565.